Printer Friendly

PHARMACEUTICAL RESOURCES SUBSIDIARY SUED

 SPRING VALLEY, N.Y., June 2 /PRNewswire/ -- Pharmaceutical Resources, Inc. (NYSE, PSE: PRX) announced today that its subsidiary, Par Pharmaceutical, Inc., was sued in federal district court in Minneapolis over acts that allegedly occurred in the mid to late 1980's.
 The complaint, served yesterday on Par by Minnesota Mining and Manufacturing Company and its Riker Laboratories, Inc. subsidiary, alleges that Par gained a competitive advantage in the marketplace relative to two Riker products by obtaining FDA approvals of two Par generic drugs through such conduct as bribery of government officials and the submission of false data the FDA relating to the two Par drugs. The actions alleged to have damaged the plaintiffs were purportedly committed by certain of Par's former officers, directors or employees. The two Par products in question (Orphengesic and Orphengesic Forte) have not been manufactured or marketed by Par since 1989. The lawsuit seeks relief under the Lanham Trademark Act, the Racketeer Influenced and Corrupt Organizations (RICO) Act, Minnesota's deceptive trade practices statute, and common law.
 Kenneth I. Sawyer, president of Pharmaceutical Resources, said "We shall defend this lawsuit vigorously." He also noted that "this lawsuit does not raise any concerns about the present integrity and reputation of Par or any part of our current product line. Rather, the allegations relate to the conduct of certain former Par officials who have had no relationship with Par for years and that also have been the subject of well-publicized investigation by the Justice Department, shareholder derivative and class actions, and a lawsuit by another competitor that was dismissed with prejudice in December and that is presently on appeal."
 Pharmaceutical Resources, Inc. through its subsidiaries, manufactures and markets prescription and over-the-counter pharmaceuticals.
 -0- 6/2/93
 /CONTACT: Kenneth I. Sawyer, president, or Michael A. Swit of Pharmaceutical Resources, Inc., 914-425-7100/
 (PRX)


CO: Pharmaceutical Resources, Inc.; Par Pharmaceutical, Inc. ST: New York, Minnesota IN: MTC SU:

WB-SM -- NY087 -- 4654 06/02/93 17:36 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1993
Words:324
Previous Article:CAPITAL AUTO RECEIVABLES ASSET TRUST 1993-2 (ISSUER) $750,000,000 CLASS A-1 3.35 PERCENT ASSET BACKED NOTES RATED 'DUFF 1+' AND 'AAA'
Next Article:M-WAVE, INC. PATENTS FLEXLINK TM PROCESS
Topics:


Related Articles
PHARMACEUTICAL RESOURCES REACHES AGREEMENT TO SETTLE INVESTIGATION BY SECURITIES AND EXCHANGE COMMISSION
PHARMACEUTICAL RESOURCES ANNOUNCES SETTLEMENT OF FINAL ASPECT OF SHAREHOLDER LAWSUITS
AMGEN AND CHUGAI REACH AGREEMENT ON G-CSF PATENT DISPUTE
PHARMACEUTICAL RESOURCES REPORTS COURT OF APPEALS DECISION
PHARMACEUTICAL RESOURCES, INC. ANNOUNCES SETTLEMENT OF LAWSUIT WITH MYLAN LABORATORIES, INC.
PHARMACEUTICAL RESOURCES ANNOUNCES SETTLEMENT OF LAWSUIT WITH MINNESOTA MINING & MANUFACTURING ("3M")
GENERICA LIMITED SUES AKZO NOBEL, INC., PHARMACEUTICALS BASICS AND ROSEMONT PHARMACEUTICAL TO ENFORCE $7 MILLION ARBITRATION AWARD
JUDGE RULES ON TECHNICALITY IN FUJISAWA USA, INC. SUIT; STATE CAUSE OF ACTION STILL OPEN
Avatex Calls Defendants' Actions in Foxmeyer Conspiracy Case 'Desperate Legal Maneuvering'
Pharmaceutical Resources prevails in interference proceeding.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters